Sort   by:  
 Page size 
ProteomicsComparative proteomics and phosphoproteomics analyses of glucocorticoid responses in breast cancer cell lines
Breast cancer is often treated with glucocorticoids together with chemotherapy to relieve its side effects. However, it has been reported that glucocorticoids promote metastasis of breast cancer. In this study, we conducted quantitative mass-spectrometry to acquire proteome and phosphoproteome to un...
ORGANISM(S): Homo sapiens (Human) 
2026-01-26 | PXD070780 | Pride
Phosphoproteome Glucocorticoid Breast cancer Proteome 
ProteomicsHuman neutrophil phosphoproteome after glucocorticoid treatment
Glucocorticoids (GCs) are corticosteroid hormones that are commonly used for treating systemic inflammatory diseases and acute infections. Immunosuppressive effects of GCs have been studied in many cell types, particularly macrophages and T cells. Despite the importance and abundance of neutrophils ...
ORGANISM(S): Homo sapiens (Human) 
2026-01-15 | PXD069234 | Pride
Phosphoproteome Neutrophil Glucocorticoid Human 
ProteomicsHuman neutrophils treated with glucocorticoids LC-MS/MS
Human neutrophils and neutrophil-like cells were differentiated from HL-60 cells. Cells were treated with glucocorticoids, dexamethasone or prednisolone, for proteome and phosphoproteome analysis.
ORGANISM(S): Homo sapiens (Human) 
2026-01-15 | PXD064627 | Pride
Human Phosphoproteome Neutrophil Glucocorticoid Proteome 
ProteomicsHuman HL-60 cell differentiated neutrophil-like cells treated with glucocorticoid LC-MS/MS
In this study, we performed deep proteome analysis of neutrophil-like cells (NLCs) after glucocorticoid regulator treatment using a quantitative mass-spectrometry approach.
ORGANISM(S): Homo sapiens (Human) 
2026-01-15 | PXD064322 | Pride
Human Glucocorticoid Astral Lc-ms/ms 
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
Sort   by:  
 Page size